News archive
Our CEO Dorte X Gram will be attending the Nordic Life Science Days 2023.
Nordic Life Science will be held for the first time and for its 10th anniversary in Copenhagen, Denmark at Bella Arena
(20 Nov-2023)
CEO Dorte X. Gram presenting PILA PHARMA’s diabete drug project for the treatment of type 2 diabetes at the Diabetes Event hosted by Redeye.
Please, find the link to the video (in English) here
(26 May-2023)
CEO Dorte X. Gram presenting PILA PHARMA’s new orphan drug project for the treatment of rare disease Erythromelalgia at the Orphan Drugs day hosted by Redeye.
Please, find the link to the video (in English) here
Happy to have been featured with the frontpage and a good article this week in the special section “Hälsa & Forskning” from Swedish newspaper Svenska Dagbladet!
It elaborates a little on our increased focus on our orphan drug designation and the perspectives and possibilities it gives.
Dorte X. Gram / Elna Lembrér Åström / Gustav Hanghøj Gram
Läs (in Swedish) här
(15 April-2023)
Presentation from the 15th annual Lifescience Capital Markets day in Stockholm hosted by Stockholm Corporate Finance and Financial Hearings. CEO, Dorte X. Gram gives a brief update on the company, status and thoughts/plans for the next foreseeable future.
Please, find the link to the video (in English) here
(10 March-2023)
Bokslutskommuniké 1 JANUARI – 31 DECEMBER 2022
Läs rapporten PDF (in Swedish) här
(28-February-2022)
LSX Inv€$tival, London 13 November
Our team is pleased to be back in London for the LSX Inv€$tival day-conference. We look forward to update investors and potential pharma partners on our progress and plans and to discuss 1-to-1 on how our TRPV1 solution for treatment of obesity, diabetes and CVD aligns attractively with the obesity market and its new treatment
Please Follow the event here
LSX Nordic, Copenhagen 10-11 October
Our team is delighted to participate in LSX Nordic in Copenhagen. We are pleased to have a presentation slot on Wednesday at 11:15am and look forward to meaningful partnering and financing discussions. We welcome investors for 1-to-1 meetings at the venue to discuss our TRPV1 solution for treatment of obesity, diabetes, CVD & more
Please Follow the event here
Our CEO Dorte X. Gram will be participating in the Annual meeting of the European Association for the Study of Diabetes and will be available for meetings.
Please request meeting at info@pilapharma.com
Our CEO Dorte X. Gram will be presenting a status update to Swedish investors.
Streaming available here
Our CEO Dorte X. Gram will be presenting a status update to Danish investors (no streaming)
Sign up to participate on-site here
ADA AMERICAN DIABETES ASSOCIATION CONVENTION – SAN DIEGO 2023
Our CEO Dorte X. Gram will be attending the ADA and is available for meetings regarding our diabetes project.
SAN DIEGO, CA / CONVENTION CENTER | JUNE 23-26, 2023
BIO INTERNATIONAL CONVENTION – BOSTON 2023
Our CEO Dorte X. Gram will be attending BIO and is available for meetings regarding both our diabetes and orphan (erythromelalgia) projects
June 5-8, 2023・Boston Convention & Exhibition Center – Boston, MA
2023 REDEYE THEME DAY: DIABETES
Our CEO Dorte X. Gram will be presenting an update on our diabetes project
The presentation can be viewed online on 24 May here
Meet our CEO, Dorte X. Gram at:
Bio€quity Europe 2023, Dublin
Please, Register here
(03 May-2023)
Anglonordic Life Science Conference 2023
19-20 april, London, UK here
(06 April-2023)
NORDIC RARE DISEASE SUMMIT 2023
17 april, Stockholm, Sweden here
(06 April-2023)
We’re delighted to be in Stockholm this Thursday, March 9th, where our CEO Dorte X. Gram will present at the 15th Lifescience Capital Marketsday hosted by Stockholm Corporate Finance and FinancialHearings!
Dorte X. Gram will take the stage at 10:45!
Sign up in the link below for live or digital participation: https://lnkd.in/eZrgfJvW
(07-March-2023)
Dorte X. Gram, CEO presenterar på Redeye Investor AW – Göteborg
Please, find the link to the video (in English) here
(10-November-2022)
INBJUDAN TILL TECKNING AV AKTIER I PILA PHARMA AB (PUBL)
Läs Memorandum PDF (in Swedish) här
